THOUSAND OAKS, Calif.,
April 27, 2017 /PRNewswire/
-- Amgen (NASDAQ:AMGN) today announced plans to participate in
the World Medical Innovation Forum™ focused on cardiovascular
disease held May 1-3, 2017, in
Boston. The World Medical
Innovation Forum is a global gathering of senior corporate,
investor and academic leaders. The forum was established to respond
to the intensifying transformation of health care and its impact on
innovation. This is the third year Amgen has participated in this
event as a sponsor.
Four senior leaders from Amgen are scheduled to speak:
- Robert A. Bradway, chairman and
chief executive officer, will participate in a fireside chat with
Scott Sperling, co-president, Thomas
H. Lee Partners. The discussion will highlight Amgen's strategic
focus in cardiovascular disease, its commitment to unlocking value
through innovative therapeutics that address serious illness, and
its approach to innovation. The fireside chat is scheduled for
11:15 a.m. ET on Tuesday, May 2.
- Sean E. Harper, M.D., executive
vice president of Research and Development, will participate in a
session on "Precision Cardiovascular Medicine: What is Different
This Time" moderated by Alex de
Winter, Ph.D., managing director, GE Ventures. The
conversation will examine the impact of combined phenotypic and
genotypic characterization on optimizing response to therapeutics,
trial design, improving outcomes, and redefining reimbursement. The
session is scheduled for 2 p.m. ET on
Tuesday, May 2.
- Scott M. Wasserman, M.D., vice
president of Global Development, will present on the "Global
Clinical Trials: Next Generation Design and Scalability" panel
moderated by Marc Sabatine, M.D.,
chairman TIMI Study Group, Lewis
Dexter, MD Distinguished Chair in Cardiovascular Medicine,
Brigham and Women's Hospital. The expert panel members will discuss
design and implementation of clinical studies globally, with a
focus on strategies for patient access, regulatory implications,
cost containment, and management of relationships with global
service providers. The panel is scheduled for 1:10 p.m. ET on Tuesday,
May 2.
- Aariff Khakoo, M.D., vice president of Cardiometabolic
Disorders Research, will present on the "New Targets in Coronary
Artery Disease" panel moderated by Sekar
Kathiresan, M.D., director of the Center for Human Genetic
Research at Massachusetts General Hospital and associate professor
of medicine at Harvard Medical School.
The expert panel members will review the design and implementation
of clinical studies globally, with a focus on strategies for
patient access, leveraging electronic health records and mobile
device data, personalized medicine, regulatory implications, cost
containment, and management of relationships with global service
providers. The panel is scheduled for 9:15
a.m. ET on Wednesday, May
3.
The above sessions will take place at The Westin Copley Place in
Boston. Mr. Bradway's discussion
will be hosted in the GE Ballroom and the other sessions will be
held in the Boston Scientific Ballroom.
About Amgen in the Cardiovascular Therapeutic
Area
Building on more than three decades of experience in
developing biotechnology medicines for patients with serious
illnesses, Amgen is dedicated to addressing important
scientific questions to advance care and improve the lives of
patients with cardiovascular disease, the leading cause of
morbidity and mortality
worldwide.1 Amgen's research into
cardiovascular disease, and potential treatment options, is part of
a growing competency at Amgen that utilizes human
genetics to identify and validate certain drug targets. Through its
own research and development efforts, as well as
partnerships, Amgen is building a robust cardiovascular
portfolio consisting of several approved and investigational
molecules in an effort to address a number of today's important
unmet patient needs, such as high cholesterol and heart
failure.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains
forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including estimates of revenues,
operating margins, capital expenditures, cash, other financial
metrics, expected legal, arbitration, political, regulatory or
clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed
below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most recent annual
report on Form 10-K and any subsequent periodic reports on Form
10-Q and Form 8-K. Unless otherwise noted, Amgen is providing
this information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted
by government investigations, litigation and product liability
claims. In addition, our business may be impacted by the adoption
of new tax legislation or exposure to additional tax liabilities.
If we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Further, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors, or we
may fail to prevail in present and future intellectual property
litigation. We perform a substantial amount of our commercial
manufacturing activities at a few key facilities and also depend on
third parties for a portion of our manufacturing activities, and
limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete
with other companies with respect to many of our marketed products
as well as for the discovery and development of new products.
Discovery or identification of new product candidates cannot be
guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product
candidate will be successful and become a commercial product.
Further, some raw materials, medical devices and component parts
for our products are supplied by sole third-party suppliers.
Certain of our distributors, customers and payers have substantial
purchasing leverage in their dealings with us. The discovery of
significant problems with a product similar to one of our products
that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our
business and results of operations. Our efforts to acquire other
companies or products and to integrate the operations of companies
we have acquired may not be successful. We may not be able to
access the capital and credit markets on terms that are favorable
to us, or at all. We are increasingly dependent on information
technology systems, infrastructure and data security. Our stock
price is volatile and may be affected by a number of events. Our
business performance could affect or limit the ability of our Board
of Directors to declare a dividend or our ability to pay a dividend
or repurchase our common stock.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Kristen Neese, 805-313-8267
(media)
Arvind Sood, 805-447-1060
(investors)
1 World Health Organization. Cardiovascular diseases
(CVDs) fact sheet.
http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed
February 2017.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-to-participate-in-the-2017-world-medical-innovation-forum-focused-on-cardiovascular-disease-300447513.html
SOURCE Amgen